Recently Featured

Expert Proposes Independent Testing to Enhance Trust in Generic Drug Quality

July 3, 2026
Generic drugs represent approximately 90% of prescriptions in the United States, largely due to their cost-effectiveness. However, the reliability of these medications has come under scrutiny, with over 60% of shortages linked to quality issues, as reported by the Food and Drug Administration (FDA). Many generic manufacturers, particularly those based in India, have faced citations…

ProMed Pharma Secures Second Dedicated Manufacturing Suite Agreement at Niagara Lane Facility

July 3, 2026
PLYMOUTH, MN, UNITED STATES, – ProMed Pharma, a leading contract development and manufacturing organization (CDMO) specializing in long-acting injectable and implantable drug delivery systems, has announced a significant agreement to establish a second dedicated manufacturing suite at its Niagara Lane facility in Plymouth, Minnesota. This suite will be tailored for the handling and manufacture of…

BIO 2026: NVIDIA announces the BioNeMo toolkit for AI agents

July 3, 2026
NVIDIA has unveiled the BioNeMo toolkit at BIO 2026, a suite of advanced tools aimed at enhancing the capabilities of artificial intelligence in pharmaceutical research and development. This toolkit is designed to enable AI systems to conduct R&D tasks with increased speed and reliability, fostering a continuous innovation loop that could significantly accelerate drug discovery…

Three Subtypes of Severe Pneumonia Might Inform Personalized Therapies

July 3, 2026
A study led by researchers at the University of Cambridge has identified three distinct subtypes of severe pneumonia, termed “pneumotypes,” which could significantly influence patient recovery in intensive care settings. By analyzing lung fluid from patients rather than relying solely on traditional symptom assessments, the researchers found that these pneumotypes corresponded to varied recovery outcomes,…

Ongoing Cases